(2R,3S,4S)-4-(2-Hydroxy-pentadecyl)-3-(2-methoxy-ethoxy)-oxetan-2-one | 1151391-97-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2R,3S,4S)-4-(2-Hydroxy-pentadecyl)-3-(2-methoxy-ethoxy)-oxetan-2-one
• 英文别名: (3S,4S)-4-[(2R)-2-hydroxypentadecyl]-3-(2-methoxyethoxy)oxetan-2-one
• CAS: 1151391-97-7
• 化学式: C₂₁H₄₀O₅
• 分子量: 372.546
• InChiKey: XMIDDHNNIYFOGZ-AABGKKOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  26
• 可旋转键数：
  18
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• BETA-LACTONE COMPOUNDS
  申请人：Smith Jeffrey W.

  公开号：US20090124681A1

  公开（公告）日：2009-05-14

  The present invention provides compounds having the general structure A, or a pharmaceutically acceptable derivatives thereof: wherein R is an alkyl group, and R 1 comprises at least one moiety selected from a group consisting of an alkyl, an alkenyl, an aryl, a heterocycle, hydroxyl, ester, amido, aldehyde, and a halogen.

  本发明提供具有一般结构A的化合物，或其药学上可接受的衍生物：其中R是烷基基团，R1包括至少一种从烷基、烯基、芳基、杂环、羟基、酯、酰胺、醛基和卤素组成的基团。
• US8258321B2
  申请人：——

  公开号：US8258321B2

  公开（公告）日：2012-09-04
• [EN] BETA-LACTONE COMPOUNDS<br/>[FR] COMPOSÉS DE BÊTA-LACTONE
  申请人：BURNHAM INST MEDICAL RESEARCH

  公开号：WO2009059046A1

  公开（公告）日：2009-05-07

  The present invention provides compounds having the general structure A3 or a pharmaceutically acceptable derivatives thereof: wherein R is an alkyl group, and Ri comprises at least one moiety selected from a group consisting of an alkyl, an alkenyl, an aryl, a heterocycle, hydroxyl, ester, amido, aldehyde, and a halogen.
• [EN] METHOD AND COMPOSITIONS FOR TREATING OBESITY AND INSULIN RESISTANCE<br/>[FR] MÉTHODE ET COMPOSITIONS DE TRAITEMENT DE L'OBÉSITÉ ET DE LA RÉSISTANCE À L'INSULINE
  申请人：OKLAHOMA MED RES FOUND

  公开号：WO2019112996A1

  公开（公告）日：2019-06-13

  The present invention provides a method of treating obesity in a patient by upregulation of mitochondrial chaperones comprising the steps of: providing a pharmaceutically effective amount of a cDNA composition encoding one or more cellular proteins to increase the one or more cellular proteins in the cell and reduced adiposity in the patient.